Dr Mustafa Khasraw

Oncology Senior Research Fellow and Clinical Lead
NHMRC Clinical Trials Centre, Sydney Medical School and Medical Oncologist at Royal North Shore Hospital in Sydney


Map

Biographical details

Dr Mustafa Khasraw is a medical oncologist at Royal North Shore Hospital in Sydney. He is also a senior research fellow at the NHMRC Clinical Trials Centre of The University of Sydney, Clinical Lead for the Cooperative Trials Group for Neuro-Oncology (COGNO), cancer research fellow at Deakin University with leading role in several clinical and translational laboratory programs.

Research interests

Clinical Trials to Improve Outcomes of Cancer Patients

Current projects

Coordination principal investigator/ study chair of multicenter trials:

· The VERTU study: VEliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma

· NEONAB: Tailored Neoadjuvant Epirubicin And Cyclophosphamide (EC) And Nanoparticle Albumin Bound (nab) Paclitaxel For Newly Diagnosed Breast Cancer

· NABNEC: NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

· Australian Liaison and Executive Committee member for The international GBM AGILE trial (an Adaptive, Global, Innovative Learning Environment)

Associations

Academic, community and other activities:

  • 2016 Grant Review Panel member, and since 2012 External Reviewer for NHMRC grants.
  • 2016-2017: Medicare MBS review taskforce member
  • 2015-ongoing: Northern Sydney Local Area Health Human Research Ethics Committee member
  • 2016 Chair of the scientific program of the Asian Society of neurooncology meeting
  • 2015-2016: Cancer Australia Breast Cancer Best Practice advisory group
  • 2014-ongoing: Scientific Advisory and Grant Review Committee of the Cure Brain cancer Foundation
  • 2011-2015: Member of Barwon Health Research Review Committee
  • 2012: Member of the Grants Review Committee of the Cancer Australia Priority Driven Collaborative Research Scheme (PdCCRS).
  • 2012-ongoing: Medical co-director of Rotary Bowel Scan in the Geelong area VIC
  • 2012-ongoing: Medical Oncology Group of Australia expert panel in breast cancer, neurooncology and neuroendocrine tumour advisory groups.
  • 2012 Cancer Australia (CNS) metastases in secondary breast cancer Working Group
  • 2012-ongoing: Breast Cancer Network Australia's Strategic Advisory Group member
  • 2012 Organizing committees member: Medical oncology Group of Australia Annual Scientific Meeting
  • 2012 -2013: The Cooperative Trials Group for Neuro-Oncology (COGNO) organising committee member and Convener of the 2014 Annual Scientific Meeting.
  • 2014-ongoing: EviQ Cancer Institute NSW lung cancer and neurooncology groups member
  • 2013-ongoing: Cancer Council NSW Lung Cancer Clinical Practice Guidelines (online Wiki)
  • 2011-ongoing: ANZ Breast Cancer Trial Group scientific advisory/ therapeutic sub-committee member

In the media

International links

United States

(Arizona State University, M.D Anderson, Harvard, University of California Los Angeles, Memorial Sloan-Kettering cancer Center. ) Collaborations across multiple USA institutions including both clinical and translational studies

Selected grants

2017

  • A 2:1 Randomised Phase II Study of NivolUmab and Temozolomide vs Temozolomide in Methylated newly diagnosed Elderly Glioblastoma (NUTMEG); Khasraw M, Rosenthal M, McDonald K, Ashley D; National Health and Medical Research Council (NHMRC)/Project Grants.

2016

  • A Randomised Phase II Study of nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (NABNEC); Khasraw M, Lipton L, Chantrill L, Hofman M, Wilson C, Michael M, Christie M, Gill A; National Health and Medical Research Council (NHMRC)/Project Grants.
  • VERTU - VEliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma; Khasraw M, Simes R, Rosenthal M, McDonald K, Koh E, Ashley D, Buckland M, Barnes E, Goh C, Yip S; Cancer Council New South Wales/Priority-driven Collaborative Cancer Research Scheme.

2015

  • VERTU – VEliparib, Radiotherapy and Temozolimde trial in newly diagnosed Unmethylated MGMT Glioblastoma; Khasraw M, Simes R; Cure Brain Cancer Foundation/Research Grant.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Khasraw, M., Noy, A., Gilbert, M., Omuro, A. (2012). Neurological Complications of Non-Hodgkin Lymphoma. In Tracy Batchelor, Lisa M DeAngelis (Eds.), Lymphoma and Leukemia of the Nervous System, (pp. 267-286). New York: Springer Science+Business Media. [More Information]
  • Khasraw, M., Khakoo, Y. (2012). Paraneoplastic Syndromes Affecting the Nervous System. In Kenneth F. Swaiman, Stephen Ashwal, Donna M Ferriero, Nina F Schor (Eds.), Swaiman's Pediatric Neurology: Principles and Practice, 5th Ed, (pp. 1388-1394). Canada: Elsevier Inc.

Journals

  • Wong, S., Norman, R., Dunning, T., Ashley, D., Khasraw, M., Hayes, T., Collins, I., Lorgelly, P. (2016). A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments. Journal of the National Comprehensive Cancer Network, 14(3), 311-319.
  • Khasraw, M., Lee, A., McCowatt, S., Kerestes, Z., Buyse, M., Back, M., Kichenadasse, G., Ackland, S., Wheeler, H. (2016). Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. Journal of Neuro-Oncology, 128(1), 163-171. [More Information]
  • Field, K., Rosenthal, M., Khasraw, M., Sawkins, K., Nowak, A. (2016). Evolving management of low grade glioma: No consensus amongst treating clinicians. Journal of Clinical Neuroscience, 23, 81-87. [More Information]
  • Segelov, E., Waring, P., Desai, J., Wilson, K., Gebski, V., Thavaneswaran, S., Elez, E., Underhill, C., Pavlakis, N., Khasraw, M., et al (2016). ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 16(1), 1-8. [More Information]
  • Garber, S., Hashimoto, Y., Weathers, S., Xiu, J., Gatalica, Z., Verhaak, R., Zhou, S., Fuller, G., Khasraw, M., de Groot, J., et al (2016). Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology, 18(10), 1357-1366. [More Information]
  • Khasraw, M., Ananda, S., Michael, M. (2016). Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 16(4), 391-401. [More Information]
  • Hodges, T., Ferguson, S., Caruso, H., Kohanbash, G., Zhou, S., Cloughesy, T., Berger, M., Poste, G., Khasraw, M., Ba, S., et al (2016). Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 5(6), 1-19. [More Information]
  • Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Robledo, K., Gebski, V., Elez, E., Nott, L., Karapetis, C., Lunke, S., Pavlakis, N., Khasraw, M., Wilson, K., Simes, R., et al (2016). Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology, 34(19), 2258-2264. [More Information]
  • Wong, S., Matheson, L., Morrissy, K., Pitson, G., Ashley, D., Khasraw, M., Lorgelly, P., Henry, M. (2016). Retrospective analysis of cancer survival across South-Western Victoria in Australia. Australian Journal of Rural Health, 24(2), 79-84. [More Information]
  • Wann, A., Ashley, D., Khasraw, M. (2016). Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre. Supportive Care in Cancer, 24(7), 3023-3028. [More Information]
  • Dukelow, T., Kishan, D., Khasraw, M., Murphy, C. (2015). CDK4/6 inhibitors in breast cancer. Anti-Cancer Drugs, 26(8), 797-806. [More Information]
  • Wang, T., Gantier, M., Xiang, D., Bean, A., Bruce, M., Zhou, S., Khasraw, M., Ward, A., Wang, L., Wei, M., et al (2015). EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Theranostics, 5(12), 1456-1472. [More Information]
  • Khasraw, M., Ameratunga, M., Grant, R., Wheeler, H., Pavlakis, N. (2014). Antiangiogenic therapy for high-grade glioma. Cochrane Database of Systematic Reviews, 2014 (9), 1-42. [More Information]
  • Khasraw, M., Ameratunga, M., Grommes, C. (2014). Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. Expert Opinion on Biological Therapy, 14(5), 729-740. [More Information]
  • Hao-Wen, S., Morris, P., Patil, S., Khasraw, M. (2014). Brain metastases in breast cancer. Expert Review of Anticancer Therapy, 14(2), 173-183. [More Information]
  • Ameratunga, M., Pavlakis, N., Gebski, V., Broad, A., Khasraw, M. (2014). Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis. Asia-Pacific Journal of Clinical Oncology, 10(3), 273-278. [More Information]
  • Gupta, S., Tran, T., Luo, W., Phung, D., Kennedy, R., Broad, A., Campbell, D., Kipp, D., Singh, M., Khasraw, M., et al (2014). Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry. BMJ Open, 4(3), 1-7. [More Information]
  • Cosman, R., Brown, C., DeBraganca, K., Khasraw, M. (2014). Patterns of care in adult medulloblastoma: results of an international online survey. Journal of Neuro-Oncology, 120(1), 125-129. [More Information]
  • Harvey, S., Khasraw, M. (2013). Alternative targeted therapy for early HER2 positive breast cancer. Unknown, 2(1), 42-45.
  • Davis, J., Ahlberg, F., Berk, M., Ashley, D., Khasraw, M. (2013). Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurology, 13, 1-9. [More Information]
  • Lomax, A., Yap, S., Khasraw, M. (2013). Intraaortic metastases or intraarterial thrombus. International Journal of Case Reports and Images, 4(7), 368-371.
  • Khasraw, M., Yap, S., Ananda, S. (2013). Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 13(4), 451-459. [More Information]
  • Omuro, A., Chan, T., Abrey, L., Khasraw, M., Reiner, A., Kaley, T., DeAngelis, L., Lassman, A., Nolan, C., Gavrilovic, I., et al (2013). Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology, 15(2), 242-250. [More Information]
  • Domchek, S., Jhaveri, K., Patil, S., Stopfer, J., Hudis, C., Powers, J., Stadler, Z., Goldstein, L., Kauff, N., Khasraw, M., et al (2013). Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer, 119(7), 1344-1348. [More Information]
  • Mustafa, B., Samaan, M., Langmead, L., Khasraw, M. (2013). Small bowel video capsule endoscopy: an overview. Expert Review of Gastroenterology and Hepatology, 7(4), 323-329. [More Information]
  • Khasraw, M., Simeonovic, M., Grommes, C. (2012). Bevacizumab for the treatment of high-grade glioma. Expert Opinion on Biological Therapy, 12(8), 1101-1111. [More Information]
  • Sheet, S., Sheikha, A., Saeed, A., Ameen, H., Mohammed, S., Khasraw, M. (2012). Colorectal cancer: is the incidence rising in young Iraqi patients? Asia-Pacific Journal of Clinical Oncology, 8(4), 380-381. [More Information]
  • Khasraw, M., Bell, R., Dang, C. (2012). Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. The Breast, 21(2), 142-149. [More Information]
  • Khasraw, M., Harvey, S., Bell, R. (2012). Hormonal Resistance in Breast Cancer: Evolving Treatment Strategies. Current Breast Cancer Reports, 4(1), 66-74. [More Information]
  • Khasraw, M., Holodny, A., Goldlust, S., DeAngelis, L. (2012). Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Annals of Oncology, 23(2), 458-463. [More Information]
  • Khasraw, M., Bell, R. (2012). Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Review of Anticancer Therapy, 12(8), 1005-1013. [More Information]
  • Khasraw, M., Ashley, D., Wheeler, G., Berk, M. (2012). Using lithium as a neuroprotective agent in patients with cancer. BMC Medicine, 10, 1-7. [More Information]
  • Khasraw, M., Robson, M. (2011). Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. Clinical Investigation, 1(11), 1545-1554. [More Information]
  • Khasraw, M., Brogi, E., Seidman, A. (2011). The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury? Current Oncology Reports, 13(1), 17-25. [More Information]
  • Khasraw, M., Lassman, A. (2010). Advances in the Treatment of Malignant Gliomas. Current Oncology Reports, 12(1), 26-33. [More Information]
  • Khasraw, M., Lassman, A., Wheeler, H., Pavlakis, N. (2010). Anti-angiogenic therapy for high grade glioma (Protocol). Cochrane Database of Systematic Reviews, 2010 (2), 1-9.
  • Murphy, C., Khasraw, M., Seidman, A. (2010). Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment, 122(1), 177-179. [More Information]
  • Khasraw, M., Pavlakis, N., McCowatt, S., Underhill, C., Begbie, S., De Souza, P., Boyce, A., Parnis, F., Lim, V., Harvie, R., et al (2010). Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology, 21(6), 1302-1307. [More Information]
  • Khasraw, M., Posner, J. (2010). Neurological complications of systemic cancer. The Lancet Neurology, 9(12), 1214-1227. [More Information]
  • Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal, 40(6), 453-458. [More Information]
  • Khasraw, M., Faraj, H., Sheikha, A. (2010). Thrombocytopenia in Solid Tumors. European Journal of Clinical & Medical Oncology, 2(2), 1-4.
  • Khasraw, M., Atkinson, C., Van der Saag, D., Pavlakis, N., Guminski, A. (2009). Cardiac toxicity from sunitinib: Do we need to be more vigilant? Asia-Pacific Journal of Clinical Oncology, 5(4), 217-218. [More Information]
  • Khasraw, M., Baron-Hay, S. (2009). Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP? Annals of Oncology, 20(7), 1282-1283. [More Information]
  • Khasraw, M., Bell, D., Wheeler, H. (2009). Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas? Journal of Clinical Neuroscience, 16(6), 854-855. [More Information]
  • Khasraw, M., Gill, A., Harrington, T., Pavlakis, N., Modlin, I. (2009). Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis. Journal of Clinical Gastroenterology, 43(9), 838-47. [More Information]
  • Khasraw, M., Lassman, A. (2009). Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma. Nature Reviews Neurology, 5(12), 646-647. [More Information]
  • Khasraw, M., Marx, G. (2008). Chemotherapy in the Elderly. Cancer Forum, 32(1), 1-4.

2016

  • Wong, S., Norman, R., Dunning, T., Ashley, D., Khasraw, M., Hayes, T., Collins, I., Lorgelly, P. (2016). A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments. Journal of the National Comprehensive Cancer Network, 14(3), 311-319.
  • Khasraw, M., Lee, A., McCowatt, S., Kerestes, Z., Buyse, M., Back, M., Kichenadasse, G., Ackland, S., Wheeler, H. (2016). Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. Journal of Neuro-Oncology, 128(1), 163-171. [More Information]
  • Field, K., Rosenthal, M., Khasraw, M., Sawkins, K., Nowak, A. (2016). Evolving management of low grade glioma: No consensus amongst treating clinicians. Journal of Clinical Neuroscience, 23, 81-87. [More Information]
  • Segelov, E., Waring, P., Desai, J., Wilson, K., Gebski, V., Thavaneswaran, S., Elez, E., Underhill, C., Pavlakis, N., Khasraw, M., et al (2016). ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 16(1), 1-8. [More Information]
  • Garber, S., Hashimoto, Y., Weathers, S., Xiu, J., Gatalica, Z., Verhaak, R., Zhou, S., Fuller, G., Khasraw, M., de Groot, J., et al (2016). Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology, 18(10), 1357-1366. [More Information]
  • Khasraw, M., Ananda, S., Michael, M. (2016). Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 16(4), 391-401. [More Information]
  • Hodges, T., Ferguson, S., Caruso, H., Kohanbash, G., Zhou, S., Cloughesy, T., Berger, M., Poste, G., Khasraw, M., Ba, S., et al (2016). Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 5(6), 1-19. [More Information]
  • Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Robledo, K., Gebski, V., Elez, E., Nott, L., Karapetis, C., Lunke, S., Pavlakis, N., Khasraw, M., Wilson, K., Simes, R., et al (2016). Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. Journal of Clinical Oncology, 34(19), 2258-2264. [More Information]
  • Wong, S., Matheson, L., Morrissy, K., Pitson, G., Ashley, D., Khasraw, M., Lorgelly, P., Henry, M. (2016). Retrospective analysis of cancer survival across South-Western Victoria in Australia. Australian Journal of Rural Health, 24(2), 79-84. [More Information]
  • Wann, A., Ashley, D., Khasraw, M. (2016). Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre. Supportive Care in Cancer, 24(7), 3023-3028. [More Information]

2015

  • Dukelow, T., Kishan, D., Khasraw, M., Murphy, C. (2015). CDK4/6 inhibitors in breast cancer. Anti-Cancer Drugs, 26(8), 797-806. [More Information]
  • Wang, T., Gantier, M., Xiang, D., Bean, A., Bruce, M., Zhou, S., Khasraw, M., Ward, A., Wang, L., Wei, M., et al (2015). EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Theranostics, 5(12), 1456-1472. [More Information]

2014

  • Khasraw, M., Ameratunga, M., Grant, R., Wheeler, H., Pavlakis, N. (2014). Antiangiogenic therapy for high-grade glioma. Cochrane Database of Systematic Reviews, 2014 (9), 1-42. [More Information]
  • Khasraw, M., Ameratunga, M., Grommes, C. (2014). Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. Expert Opinion on Biological Therapy, 14(5), 729-740. [More Information]
  • Hao-Wen, S., Morris, P., Patil, S., Khasraw, M. (2014). Brain metastases in breast cancer. Expert Review of Anticancer Therapy, 14(2), 173-183. [More Information]
  • Ameratunga, M., Pavlakis, N., Gebski, V., Broad, A., Khasraw, M. (2014). Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis. Asia-Pacific Journal of Clinical Oncology, 10(3), 273-278. [More Information]
  • Gupta, S., Tran, T., Luo, W., Phung, D., Kennedy, R., Broad, A., Campbell, D., Kipp, D., Singh, M., Khasraw, M., et al (2014). Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry. BMJ Open, 4(3), 1-7. [More Information]
  • Cosman, R., Brown, C., DeBraganca, K., Khasraw, M. (2014). Patterns of care in adult medulloblastoma: results of an international online survey. Journal of Neuro-Oncology, 120(1), 125-129. [More Information]

2013

  • Harvey, S., Khasraw, M. (2013). Alternative targeted therapy for early HER2 positive breast cancer. Unknown, 2(1), 42-45.
  • Davis, J., Ahlberg, F., Berk, M., Ashley, D., Khasraw, M. (2013). Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC Neurology, 13, 1-9. [More Information]
  • Lomax, A., Yap, S., Khasraw, M. (2013). Intraaortic metastases or intraarterial thrombus. International Journal of Case Reports and Images, 4(7), 368-371.
  • Khasraw, M., Yap, S., Ananda, S. (2013). Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 13(4), 451-459. [More Information]
  • Omuro, A., Chan, T., Abrey, L., Khasraw, M., Reiner, A., Kaley, T., DeAngelis, L., Lassman, A., Nolan, C., Gavrilovic, I., et al (2013). Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-Oncology, 15(2), 242-250. [More Information]
  • Domchek, S., Jhaveri, K., Patil, S., Stopfer, J., Hudis, C., Powers, J., Stadler, Z., Goldstein, L., Kauff, N., Khasraw, M., et al (2013). Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer, 119(7), 1344-1348. [More Information]
  • Mustafa, B., Samaan, M., Langmead, L., Khasraw, M. (2013). Small bowel video capsule endoscopy: an overview. Expert Review of Gastroenterology and Hepatology, 7(4), 323-329. [More Information]

2012

  • Khasraw, M., Simeonovic, M., Grommes, C. (2012). Bevacizumab for the treatment of high-grade glioma. Expert Opinion on Biological Therapy, 12(8), 1101-1111. [More Information]
  • Sheet, S., Sheikha, A., Saeed, A., Ameen, H., Mohammed, S., Khasraw, M. (2012). Colorectal cancer: is the incidence rising in young Iraqi patients? Asia-Pacific Journal of Clinical Oncology, 8(4), 380-381. [More Information]
  • Khasraw, M., Bell, R., Dang, C. (2012). Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. The Breast, 21(2), 142-149. [More Information]
  • Khasraw, M., Harvey, S., Bell, R. (2012). Hormonal Resistance in Breast Cancer: Evolving Treatment Strategies. Current Breast Cancer Reports, 4(1), 66-74. [More Information]
  • Khasraw, M., Holodny, A., Goldlust, S., DeAngelis, L. (2012). Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. Annals of Oncology, 23(2), 458-463. [More Information]
  • Khasraw, M., Noy, A., Gilbert, M., Omuro, A. (2012). Neurological Complications of Non-Hodgkin Lymphoma. In Tracy Batchelor, Lisa M DeAngelis (Eds.), Lymphoma and Leukemia of the Nervous System, (pp. 267-286). New York: Springer Science+Business Media. [More Information]
  • Khasraw, M., Khakoo, Y. (2012). Paraneoplastic Syndromes Affecting the Nervous System. In Kenneth F. Swaiman, Stephen Ashwal, Donna M Ferriero, Nina F Schor (Eds.), Swaiman's Pediatric Neurology: Principles and Practice, 5th Ed, (pp. 1388-1394). Canada: Elsevier Inc.
  • Khasraw, M., Bell, R. (2012). Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Review of Anticancer Therapy, 12(8), 1005-1013. [More Information]
  • Khasraw, M., Ashley, D., Wheeler, G., Berk, M. (2012). Using lithium as a neuroprotective agent in patients with cancer. BMC Medicine, 10, 1-7. [More Information]

2011

  • Khasraw, M., Robson, M. (2011). Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges. Clinical Investigation, 1(11), 1545-1554. [More Information]
  • Khasraw, M., Brogi, E., Seidman, A. (2011). The Need to Examine Metastatic Tissue at the Time of Progression of Breast Cancer: Is Re-biopsy a Necessity or a Luxury? Current Oncology Reports, 13(1), 17-25. [More Information]

2010

  • Khasraw, M., Lassman, A. (2010). Advances in the Treatment of Malignant Gliomas. Current Oncology Reports, 12(1), 26-33. [More Information]
  • Khasraw, M., Lassman, A., Wheeler, H., Pavlakis, N. (2010). Anti-angiogenic therapy for high grade glioma (Protocol). Cochrane Database of Systematic Reviews, 2010 (2), 1-9.
  • Murphy, C., Khasraw, M., Seidman, A. (2010). Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Research and Treatment, 122(1), 177-179. [More Information]
  • Khasraw, M., Pavlakis, N., McCowatt, S., Underhill, C., Begbie, S., De Souza, P., Boyce, A., Parnis, F., Lim, V., Harvie, R., et al (2010). Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology, 21(6), 1302-1307. [More Information]
  • Khasraw, M., Posner, J. (2010). Neurological complications of systemic cancer. The Lancet Neurology, 9(12), 1214-1227. [More Information]
  • Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal, 40(6), 453-458. [More Information]
  • Khasraw, M., Faraj, H., Sheikha, A. (2010). Thrombocytopenia in Solid Tumors. European Journal of Clinical & Medical Oncology, 2(2), 1-4.

2009

  • Khasraw, M., Atkinson, C., Van der Saag, D., Pavlakis, N., Guminski, A. (2009). Cardiac toxicity from sunitinib: Do we need to be more vigilant? Asia-Pacific Journal of Clinical Oncology, 5(4), 217-218. [More Information]
  • Khasraw, M., Baron-Hay, S. (2009). Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP? Annals of Oncology, 20(7), 1282-1283. [More Information]
  • Khasraw, M., Bell, D., Wheeler, H. (2009). Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas? Journal of Clinical Neuroscience, 16(6), 854-855. [More Information]
  • Khasraw, M., Gill, A., Harrington, T., Pavlakis, N., Modlin, I. (2009). Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis. Journal of Clinical Gastroenterology, 43(9), 838-47. [More Information]
  • Khasraw, M., Lassman, A. (2009). Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma. Nature Reviews Neurology, 5(12), 646-647. [More Information]

2008

  • Khasraw, M., Marx, G. (2008). Chemotherapy in the Elderly. Cancer Forum, 32(1), 1-4.

To update your profile click here. For support on your academic profile contact .